First-Line HIV Treatment

The Latest

This Week in HIV Research: Unexpected Outcomes

May 2, 2019: patient-centered care model improves viral suppression; subpar immune responses when baseline CD4 tops 500; when CD4 plummets despite viral suppression; vaccination, immunoglobulin, and hepatitis A exposure.

By Barbara Jungwirth and Myles Helfand

CDC: Most HIV Transmissions Are From People Who Are Not in Care

More than 80 percent of U.S. HIV transmissions in 2016 were from people who were unaware of their status or had been diagnosed but lost to follow-up.

By Stephen Hicks

This Week in HIV Research: Prevention and Treatment in the Real World

Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.

By Barbara Jungwirth and Myles Helfand

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

By Martha Kempner

Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies

Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.

By Simon Collins for HIV i-Base

De-Simplifying Single-Tablet Regimens for HIV Treatment

A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Are Integrase Inhibitors Linked to Weight Gain? An Evidence Review

Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.

By Polly Clayden for HIV i-Base

This Week in HIV Research: Let's Get Real About Treatment Efficacy

Real-world treatment efficacy high, but falls short of trials; parental communication and PrEP awareness among adolescent MSM; immunotherapy feasible in people with HIV and cancer; AIDS-defining illness increases mortality risk in lung cancer patients.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Food, It Does a Body Good

How food insecurity feeds inflammation; racial disparities in HPV16 prevalence; how HIV meds affect pre-existing neurocognitive impairment; central nervous system inflammation in the setting of HIV treatment success.

By Barbara Jungwirth and Myles Helfand

ARVs and Children: New Research Shows the Devastating Impact of a Late Start

The first global comparison of adolescents who acquired HIV as newborns highlights the challenges around treatment for children in developing countries.

By Mary-Ann Davies and Amy Slogrove for The Conversation